This week, the CDC’s government-chartered advisory body is meeting to consider a new round of immunization recommendations ...

GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including GSK’s Arexvy (Respiratory Syncytial ...

VIMKUNYA was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 6,7.

US Advisory Committee on Immunization Practices recommends approval of GSK’s RSV vaccines, Arexvy for adults aged 50-59: London, UK Saturday, April 19, 2025, 09:00 Hrs [IST] GSK ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

For the first time since Robert F. Kennedy Jr. became health secretary, vaccine advisers to the CDC are meeting to discuss ...

The Advisory Committee on Immunization Practices’ two-day meeting is taking up vaccine policy questions that had been put on ...

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

GSK’s 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices ...

Advisory Committee on Immunization Practices (ACIP) voted to recommend the virus-like particle (VLP)-based, single-dose vaccine, VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for injection ...